Wolverine Trading’s Seres Therapeutics MCRB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-15,700
Closed -$143K 5938
2025
Q2
$143K Buy
15,700
+15,200
+3,040% +$134K ﹤0.01% 4059
2025
Q1
$7.21K Sell
500
-1,170
-70% -$18.3K ﹤0.01% 4616
2024
Q4
$27.7K Sell
1,670
-155
-8% -$2.52K ﹤0.01% 5077
2024
Q3
$33.5K Buy
1,825
+815
+81% +$16.5K ﹤0.01% 4586
2024
Q2
$14.6K Buy
+1,010
New +$16.8K ﹤0.01% 4348
2024
Q1
Sell
-2,585
Closed -$72.4K 4958
2023
Q4
$72.4K Buy
2,585
+1,550
+150% +$40.7K ﹤0.01% 4172
2023
Q3
$49.3K Sell
1,035
-245
-19% -$18.7K ﹤0.01% 4182
2023
Q2
$120K Buy
+1,280
New +$139K ﹤0.01% 3712
2022
Q3
Sell
-550
Closed -$35K 5031
2022
Q2
$35K Buy
+550
New +$47.4K ﹤0.01% 4147
2022
Q1
Sell
-915
Closed -$156K 6023
2021
Q4
$156K Buy
915
+330
+56% +$52.4K ﹤0.01% 4864
2021
Q3
$80K Sell
585
-530
-48% -$104K ﹤0.01% 5880
2021
Q2
$533K Buy
1,115
+45
+4% +$19K ﹤0.01% 3599
2021
Q1
$416K Buy
1,070
+105
+11% +$48.3K ﹤0.01% 3987
2020
Q4
$507K Buy
965
+85
+10% +$49.8K ﹤0.01% 3158
2020
Q3
$506K Buy
+880
New +$293K ﹤0.01% 2812
2019
Q4
Sell
-565
Closed -$44K 4979
2019
Q3
$44K Buy
+565
New +$37.3K ﹤0.01% 4068

Other funds holding MCRB

Wolverine Trading's MCRB Position: Q4 2024 in Review

Wolverine Trading sold out of Seres Therapeutics (MCRB) in Q4 2024, closing a stake of 1,107 shares — an estimated $18K sold.

Wolverine Trading first reported a position in MCRB in Q4 2020 and held it in 8 quarters. The position peaked at $413K in Q1 2021. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2024.

  • Wolverine Trading reported no remaining Seres Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Wolverine Trading sold 1,107 Seres Therapeutics shares in Q4 2024, an estimated $18K.
  • Wolverine Trading first reported a position in Seres Therapeutics in Q4 2020 and held it in 8 quarters.
  • Wolverine Trading's Seres Therapeutics position peaked at $413K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2024.

Based on Wolverine Trading's 13F filing for Q4 2024, filed 14 Feb 2025.